Dactinomycin injection
Products billed under this code include Dactinomycin.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Dactinomycin.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Dactinomycin | XGen Pharmaceuticals DJB, Inc. | 39822-2100-02 | 1 | $320.899 |
| Dactinomycin | Hisun Pharmaceuticals USA, Inc | 42658-0008-01 | 1 | $320.899 |
| Dactinomycin | Eugia US LLC | 55150-0431-01 | 1 | $320.899 |
| Dactinomycin | Eugia US LLC | 55150-0928-02 | 1 | $320.899 |
| Dactinomycin | Mylan Institutional Inc. | 67457-0513-05 | 1 | $320.899 |
| Dactinomycin | Mylan Institutional Inc. | 67457-0928-02 | 1 | $320.899 |
| Dactinomycin | Meitheal Pharmaceuticals Inc. | 71288-0129-02 | 1 | $320.899 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $320.899 | +$13.488 | 0.5 MG | Dactinomycin injection | v1, posted September 17, 2026 |
| 3Q26 | $307.411 | −$30.258 | 0.5 MG | Dactinomycin injection | v1, posted September 15, 2026 |
| 2Q26 | $337.669 | +$29.684 | 0.5 MG | Dactinomycin injection | v1, posted September 15, 2026 |
| 1Q26 | $307.985 | −$20.353 | 0.5 MG | Dactinomycin injection | v1, posted September 15, 2026 |
| 4Q25 | $328.338 | +$25.415 | 0.5 MG | Dactinomycin injection | v1, posted September 8, 2026 |
| 3Q25 | $302.923 | +$14.127 | 0.5 MG | Dactinomycin injection | v1, posted March 10, 2026 |
| 2Q25 | $288.796 | −$36.005 | 0.5 MG | Dactinomycin injection | v1, posted March 10, 2026 |
| 1Q25 | $324.801 | +$42.668 | 0.5 MG | Dactinomycin injection | v1, posted December 19, 2025 |
| 4Q24 | $282.133 | −$115.38 | 0.5 MG | Dactinomycin injection | v1, posted June 11, 2025 |
| 3Q24 | $397.513 | −$150.282 | 0.5 MG | Dactinomycin injection | v1, posted June 11, 2025 |
| 2Q24 | $547.795 | −$121.109 | 0.5 MG | Dactinomycin injection | v1, posted March 11, 2025 |
| 1Q24 | $668.904 | −$169.56 | 0.5 MG | Dactinomycin injection | v1, posted December 19, 2024 |
| 4Q23 | $838.464 | +$118.307 | 0.5 MG | Dactinomycin injection | v1, posted October 10, 2024 |
| 3Q23 | $720.157 | +$173.547 | 0.5 MG | Dactinomycin injection | v1, posted June 5, 2024 |
| 2Q23 | $546.61 | −$58.182 | 0.5 MG | Dactinomycin injection | v1, posted February 23, 2024 |
| 1Q23 | $604.792 | +$47.388 | 0.5 MG | Dactinomycin injection | v1, posted December 6, 2023 |
| 4Q22 | $557.404 | −$76.361 | 0.5 MG | Dactinomycin injection | v1, posted June 22, 2023 |
| 3Q22 | $633.765 | −$175.291 | 0.5 MG | Dactinomycin injection | v1, posted June 9, 2023 |
| 2Q22 | $809.056 | −$29.823 | 0.5 MG | Dactinomycin injection | v1, posted December 14, 2022 |
| 1Q22 | $838.879 | −$51.764 | 0.5 MG | Dactinomycin injection | v1, posted June 8, 2022 |
| 4Q21 | $890.643 | −$52.074 | 0.5 MG | Dactinomycin injection | v1, posted June 2, 2022 |
| 3Q21 | $942.717 | +$102.264 | 0.5 MG | Dactinomycin injection | v1, posted June 2, 2022 |
| 2Q21 | $840.453 | −$93.705 | 0.5 MG | Dactinomycin injection | v1, posted March 1, 2022 |
| 1Q21 | $934.158 | – | 0.5 MG | Dactinomycin injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.